Table 1.
Duration of survival of HSV-1 infected scid mice.
| Treatmenta | |||||
| Expt. | Virus | PBS | rabbit IgG | NK-depletedb | WBC-depletedc |
| 1 d | KOS | 15.8 ± 0.8 (n = 9) f | 34.9 ± 2.8 (n = 9) | 23.5 ± 0.9 (n = 9) | ND g |
| 2 | KOS-GFP | 19.0 ± 0.9 (n = 5) | 36.8 ± 3.8 (n = 5) | 35.0 ± 0.6 (n = 5) | ND |
| 3 e | KOS | 18.1 ± 0.8 (n = 8) | ND | ND | 12.1 ± 0.7 (n = 8) |
| 4 | KOS-GFP | 23.7 ± 1.8 (n = 6) | ND | ND | 14.0 ± 0.6 (n = 5) |
| Summary | 19.2 ± 1.7 (n = 28) | 35.9 ± 1.3 (n = 14) | 29.3 ± 5.8 (n = 14) | 13.1 ± 0.9 (n = 15) | |
a BALB/c scid mice were treated with PBS, control rabbit IgG, rabbit anti-asialo GM1, or cyclophosphamide (CyP) as described in Materials and Methods.
b BALB/c scid mice were treated with rabbit anti-asialo GM1.
c BALB/c scid mice were treated with cyclophosphamide.
d The results of Experiment 1 are presented in Figure 4.
e The results of Experiment 3 are presented in Figure 5.
f Mean ± SEM days of survival after ocular HSV-1 inoculation of scid mice (n= number of mice per treatment).
g Not determined in this experiment.